Clinical Trial

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Study acronym: SPKTAHC
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed. VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies support this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-03.
Trial Details
NCT Number NCT07636785
Lead Sponsor VM Discovery, Inc.
Conditions Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer, Colorectal Cancer (CRC)
Enrollment 111 participants
Start Date 2026-06
Primary Completion 2031-05 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-18